BioSpace News Archive

AiCuris Anti-infective Cures GmbH, a leading company in the discovery and development of drugs against infectious diseases, announced that the Company’s shareholder resolved to change the legal form from the German “GmbH” to a stock corporation.

AliveCor, the global leader in FDA-cleared personal electrocardiogram technology, launched an expanded range of ECG determinations on its KardiaMobile devices.

BIOLASE, Inc., the global leader in dental lasers, encourages stockholders to vote their shares with respect to the adjourned special meeting of stockholders initially held on January 22, 2021, which will reconvene on Tuesday, February 16, 2021.

IDEAYA Biosciences, Inc., an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics to treat cancer, announced its participation at the following upcoming investor relations events.

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company focused on developing next generation therapeutics to advance standards of care in areas of significant unmet medical need, announced topline results from the ENHANCE-IT study, the second head-to-head comparative study of LYPDISO™ vs. Vascepa®.

Thermo Fisher Scientific Inc., the world leader in serving science, reported its financial results for the fourth quarter and full year ended December 31, 2020.

Advanced intelligent Clear-IQ Engine (AiCE) Deep Learning Reconstruction (DLR) Technology Expands to Wider Range of Clinical Applications for the Vantage Orian 1.5T MR System

Gilead Sciences, Inc. and Gritstone Oncology, Inc. announced that the companies have entered into a collaboration, option and license agreement to research and develop a vaccine-based immunotherapy as part of Gilead’s efforts to find a curative treatment for human immunodeficiency virus infection.

Altima Dental Canada Holdings Inc., one of Canada’s largest and longest-standing premier groups, has launched several virtual dental tools and partnered with software developers to make dental care more accessible and convenient to Canadians.

Magellan Rx Management, a division of Magellan Health, Inc. (NASDAQ: MGLN), today released preliminary results from its oncology biosimilar medical pharmacy solution that targets new-to-market oncology therapeutic biosimilars.